0001387131-23-003349.txt : 20230313 0001387131-23-003349.hdr.sgml : 20230313 20230313070547 ACCESSION NUMBER: 0001387131-23-003349 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230313 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230313 DATE AS OF CHANGE: 20230313 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tonix Pharmaceuticals Holding Corp. CENTRAL INDEX KEY: 0001430306 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261434750 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36019 FILM NUMBER: 23725673 BUSINESS ADDRESS: STREET 1: 26 MAIN STREET, SUITE 101 CITY: CHATHAM STATE: NJ ZIP: 07928 BUSINESS PHONE: 212-980-9155 MAIL ADDRESS: STREET 1: 26 MAIN STREET, SUITE 101 CITY: CHATHAM STATE: NJ ZIP: 07928 FORMER COMPANY: FORMER CONFORMED NAME: TAMANDARE EXPLORATIONS INC. DATE OF NAME CHANGE: 20080320 8-K 1 tnxp-8k_031323.htm CURRENT REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): March 13, 2023

TONIX PHARMACEUTICALS HOLDING CORP.

(Exact name of registrant as specified in its charter)

Nevada

001-36019

26-1434750

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

26 Main Street, Chatham, New Jersey 07928

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (862) 904-8182

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	TNXP	The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02

Results of Operations and Financial Condition

On March 13, 2023, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter and year ended December 31, 2022. A copy of the press release that discusses these matters is filed as Exhibit 99.01 to, and incorporated by reference in, this report.

Item 7.01

Regulation FD Disclosure.

The Company confirms that it does not hold cash deposits or securities at Silicon Valley Bank.

The information in this Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibit

No.

Description.

99.01

104

Press release of the Company, dated March 13, 2023

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	TONIX PHARMACEUTICALS HOLDING CORP.

Date: March 13, 2023	By:	/s/ Bradley Saenger
	Bradley Saenger
	Chief Financial Officer

EX-99.01 2 ex99-01.htm PRESS RELEASE

Tonix Pharmaceuticals Holding Corp. 8-K

Exhibit 99.01

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

Interim Analysis of Registration-Enabling Phase 3 Fibromyalgia Trial of TNX-102 SL Expected Second Quarter 2023; Topline Data Expected Fourth Quarter 2023

Potentially Pivotal Phase 2 Trials of TNX-1900 in Chronic Migraine and TNX-601 ER in Depression Scheduled for Interim Analyses in Fourth Quarter 2023

Potentially Pivotal Phase 2 Fibromyalgia-Type Long COVID Study Enrolling

Cash and Cash Equivalents Totaled Approximately $120.2 Million at December 31, 2022

CHATHAM, N.J., March 13, 2023 (GLOBE NEWSWIRE) – Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided an overview of recent operational highlights.

“Our clinical activity is at a high point in the Company’s history, and we believe it is setting the stage for a year of significant accomplishments across an expanded portfolio of novel pharmaceutical candidates designed to serve major unmet medical needs,” said Seth Lederman, M.D., Chief Executive Officer of Tonix.

“We are pleased with the progress of our current Phase 3 program in fibromyalgia, and we are looking forward to the results of a planned interim analysis due next quarter, followed by topline results in the fourth quarter of this year. If successful, we believe it will be the second and final adequate and well-controlled efficacy trial required for filing a New Drug Application (NDA) for approval by the U.S. Food and Drug Administration (FDA)”, he added. “Moreover, we believe we have satisfied all the other clinical and non-clinical requirements for an NDA.”

Dr. Lederman added, “Patients and caregivers alike report widespread dissatisfaction with the three currently approved drugs for fibromyalgia—Lyrica®, Cymbalta®, and Savella®, and generic pregabalin and duloxetine--, switching back and forth between them, and too often taking off-label products, including addictive opiates. Fibromyalgia affects between six and 12 million adults in the U.S. according to the American Pain Association, and there hasn’t been a new FDA drug approval in the category in more than a dozen years.”

Dr Lederman continued, “Our recently expanded late-stage clinical programs include four potentially pivotal Phase 2 trials. Two are currently enrolling, one in Long COVID and the other in chronic migraine. The two others – one in depression and the other in cocaine intoxication – are due to start enrolling. We expect to initiate enrollment in the depression study by the end of March, followed by the cocaine intoxication study in the second quarter of this year.”

“In summary”, he concluded, “these programs, together with several others in earlier development, represent a diverse portfolio of programs with multiple opportunities for value creation in 2023 and beyond.”

Recent Highlights—Key Product Candidates*

Central Nervous System (CNS) Pipeline

TNX-102 SL (cyclobenzaprine HCl sublingual tablet): small molecule for the management of fibromyalgia (FM)

·

The first 50% of participants were randomized on December 19, 2022, in the RESILIENT study, a double-blind, randomized, placebo-controlled, potentially pivotal confirmatory Phase 3 study of TNX-102 SL for the management of fibromyalgia. Results from a planned interim analysis are expected in the second quarter of 2023, with topline results expected in the fourth quarter of 2023. A positive topline outcome, together with results from the previous positive Phase 3 RELIEF study, would support submission of an NDA.

TNX-102 SL for the treatment of Fibromyalgia-Type Long COVID, also known as Post-Acute Sequelae of COVID-19 (PASC)

·

Enrollment continues in the PREVAIL study, a potentially pivotal Phase 2 study of TNX-102 SL for fibromyalgia-type Long COVID.

·

During a February 2023 virtual event co-hosted by BIO and Solve M.E. titled, “Long COVID: What Will it Take to Accelerate Therapeutic Progress?”, the Company presented its analysis that the majority of Long COVID patients present with a constellation of symptoms called nociplastic pain that overlap with fibromyalgia, and Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) and that fibromyalgia-type Long COVID appears to be one of several chronic overlapping pain conditions (COPCs) that are related by sharing the neurological process called central sensitization.

TNX-1900 (intranasal potentiated oxytocin): small peptide for migraine, craniofacial pain, insulin resistance and related disorders, and obesity-associated binge eating disorder

·

In February 2023, Tonix announced that enrollment began in the potentially pivotal Phase 2 PREVENTION study of TNX-1900 for the prevention of migraine headache in chronic migraineurs. The double-blind, placebo-controlled study has a target enrollment of 300 participants at approximately 25 sites across the U.S. Results from a planned interim analysis after the first 50% of enrolled patients have completed the study are expected in the fourth quarter of 2023.

·

In January 2023, data from clinical and nonclinical studies were presented at the 16^th Annual Headache Cooperative of the Pacific (HCOP) Winter Conference by collaborator Professor David Yeomans. The oral presentation titled, “Primary vs Secondary Sex Hormones and Migraine,” includes research sponsored by and licensed by Tonix. Preliminary results from a positron emission tomography (PET) study in humans showed that intranasal application of a radioisotope of magnesium-potentiated oxytocin is delivered to the trigeminal ganglia which have known roles in migraine headaches. In addition, preliminary results of data collected from isolated human trigeminal ganglia neurons in vitro show co-expression of oxytocin receptors and calcitonin gene-related peptide (CGRP), which are believed to represent the first observation of oxytocin receptors in human trigeminal ganglia. Furthermore, the presentation highlights data which suggest a sex difference in oxytocin potency.

·

Tonix announced data from an in vitro study describing the impact of oxytocin on isolated human sensory neurons, presented by collaborator Professor David Yeomans at Neuroscience 2022, the annual meeting of the Society for Neuroscience. The poster, titled “In Vitro Impact of Oxytocin on Human Sensory Neurons,” is the first to show that oxytocin receptors are present on human sensory neurons and that inflammation drives expression of oxytocin receptors on these neurons. The results of this study are consistent with data from animal models and provide support for the use of oxytocin for the treatment of pain.

·

An investigator-initiated Phase 2 study of TNX-1900 in obesity-associated binge eating disorder is expected to start enrolling in the second quarter of 2023 directed by principal investigator Professor Elizabeth Lawson at the Massachusetts General Hospital, a teaching hospital of Harvard Medical School.

TNX-601 ER (tianeptine hemioxalate extended-release tablets): a once-daily orally-administered small molecule for the treatment of major depressive disorder (MDD), Posttraumatic Stress Disorder (PTSD), and neurocognitive dysfunction associated with corticosteroid use.

·

Enrollment is expected to initiate in the first quarter of 2023 in the potentially pivotal Phase 2 ‘UPLIFT’ Study for the treatment of MDD. Results from planned interim analysis after the first 50% of enrolled patients have completed the study are expected fourth quarter 2023.

·

TNX-601 ER represents a novel approach to treating depression in the U.S., since the active ingredient tianeptine induces a neuroprotective and resilient phenotype in both neurons and microglia under conditions of stress. In contrast, antidepressants that are marketed in the U.S. act by modulating neurotransmitter levels or receptor binding in the synapse. The Phase 2 UPLIFT study is a double-blind, randomized, multicenter, placebo-controlled study to evaluate the efficacy and safety of TNX-601 ER taken orally once-daily for 6 weeks to treat MDD. It is a parallel design study with two arms, a TNX-601 ER 39.4 mg arm and a placebo arm. A total of 300 participants will be randomized in a 1:1 ratio into the two arms across approximately 30 U.S. sites, enrolling adult patients 18-65 years old with a DSM-5 diagnosis of depression and a duration for the current major depressive episode (MDE) of at least 12 weeks. The primary efficacy endpoint is mean change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6. Key secondary efficacy endpoints include the Clinical Global Impression of Severity Scale (CGI-S) and the Sheehan Disability Scale (SDS).

TNX-1300 (recombinant double mutant cocaine esterase): biologic for life-threatening cocaine intoxication

·

Tonix expects to initiate a new, potentially pivotal, Phase 2 clinical study of TNX-1300 for the treatment of cocaine intoxication in the second quarter of 2023, pending agreement with the FDA on trial design.

·

As previously mentioned, in 2022, Tonix received a Cooperative Agreement grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to support development of TNX-1300.

·

TNX-1300 has been granted Breakthrough Therapy designation by the FDA.

Rare Disease Pipeline

TNX-2900 (intranasal potentiated oxytocin): small peptide for the treatment of Prader-Willi syndrome (PWS)

·

TNX-2900 has been granted Orphan Drug designation from the FDA for the treatment of PWS.

·

As previously mentioned, in 2022, Tonix delivered a presentation titled, “TNX-2900 (Intranasal Oxytocin + Magnesium) in Development for the Treatment of Hyperphagia in Adolescents and Young Adults with Prader-Willi Syndrome” at the World Orphan Drug Congress USA.

Immunology Pipeline

TNX-1500 (anti-CD40L monoclonal antibody): third generation anti-CD40L monoclonal antibody for prophylaxis of organ transplant rejection and treatment of autoimmune disorders.

·

A First-in-Human Phase 1 study is expected to start in the second quarter of 2023 of TNX-1500 for prophylaxis of organ rejection in adult patients receiving a kidney transplant.

·

In February 2023, Tonix announced a research agreement with the University of Maryland, Baltimore, to study and assess the role of TNX-1500 in the prevention of heart xenograft rejection. The genetically engineered pig donors will be provided by the Revivicor Division of United Therapeutics Corporation. Preclinical xenotransplantation studies are expected to support an IND application.

·

Tonix announced a research agreement with Boston Children’s Hospital to study TNX-1500 for the prevention of graft-versus-host diseases (GvHD) after hematopoietic stem cell transplantation (HCT) in animals. HCT from unrelated donors is a component of the treatment protocol for several hematologic malignancies, but GvHD complicates treatment and limits the success of engraftment after HCT.

Infectious Disease Pipeline

TNX-801 (live horsepox virus vaccine for percutaneous administration): vaccine to protect against smallpox and mpox designed as a single-administration vaccine to elicit T cell immunity

·

A Phase 1 study in is expected to start in the second half of 2023.

·

Tonix presented a development update from the Company’s TNX-801 vaccine program in an oral presentation at the World Vaccine and Immunotherapy Congress on December 1, 2022. The oral presentation titled, “Live Virus Smallpox and Monkeypox Vaccine,” describes the history of live virus vaccines and rationale for the development of the Company’s Recombinant Pox Virus (RPV) platform, including TNX-801 to protect against mpox and smallpox. Non-human primates vaccinated with TNX-801 were fully protected with sterilizing immunity from a lethal challenge with intra-tracheal monkeypox.

·

A publication describing the activity of TNX-801 to protect non-human primates against a lethal challenge with intra-tracheal monkeypox was published in the peer-reviewed journal, Viruses (Noyce RS, et al. “Single Dose of Recombinant Chimeric Horsepox Virus (TNX-801) Vaccination Protects Macaques from Lethal Monkeypox Challenge.” Viruses. 2023 Jan 26;15(2):356. doi: 10.3390/v15020356. PMID: 36851570; PMCID: PMC9965234.)

*All of Tonix’s product candidates are investigational new drugs or biologics and none have been approved for any indication.

Recent Highlights—Corporate and Other

·

In February 2023, Tonix announced the appointment of R. Newcomb Stillwell to its Board of Directors, effective March 15, 2023. Mr. Stillwell is a retired partner at Ropes & Gray LLP, an international law firm, where he devoted approximately 38 years.

·

In February 2023, Tonix announced that it has exercised an option to obtain an exclusive license from Columbia University for the development of a portfolio of fully human (TNX-3600) and murine (TNX-4100) monoclonal antibodies for the treatment or prophylaxis of SARS-CoV-2 infection. The licensed monoclonal antibodies were developed as part of a research collaboration and option agreement between Tonix and Columbia University, originally announced in 2020.

·

In February 2023, Tonix announced the acquisition of a preclinical portfolio of next-generation antiviral technology assets from Healion Bio, Inc. (Healion). Healion’s drug portfolio includes a class of broad-spectrum small molecule oral antiviral drug candidates including TNX-3900, formerly known as HB-121, which are cathepsin protease inhibitors, some of which have activity in vitro against SARS-CoV-2.

·

On January 26, 2023, data from Tonix’s research collaboration with The University of Alberta were presented by Tom Hobman, Ph.D., Professor of Cell Biology, University of Alberta, during a presentation at the 2^nd Wnt/β-catenin Targeted Drug Development Conference. The oral presentation titled, “Targeting the Wnt/β-catenin pathway as a broad-spectrum antiviral strategy,” includes research sponsored by Tonix Pharmaceuticals focused on the development and testing of Wnt/β-catenin signaling pathway inhibitors as broad-spectrum antivirals against SARS-CoV-2 and other emerging viruses.

·

In January 2023, Tonix announced the publication of a paper entitled, “Development of a rapid image-based high-content imaging screening assay to evaluate therapeutic antibodies against the monkeypox virus,” in the journal Antiviral Research. The publication describes the development and optimization of two high-content image-based assays that were employed to screen for potential therapeutic antibodies against the monkeypox virus using surrogate poxviruses such as vaccinia virus. The article highlights Tonix’s TNX-3400 platform, which includes antibodies to potentially prevent or treat mpox and smallpox. These data represent the first wave of research and development conducted at the Company’s Infectious Disease R&D Center (RDC) in Frederick, Md. (Kota KP, et al., “Development of a rapid image-based high-content imaging screening assay to evaluate therapeutic antibodies against the monkeypox virus.” Antiviral Res. 2023 Feb;210:105513. doi: 10.1016/j.antiviral.2022.105513. Epub 2022 Dec 30. PMID: 36592670; PMCID: PMC9803393.)

·

In January 2023, Tonix announced the appointment of Zeil Rosenberg, M.D., M.P.H. as its new Executive Vice President, Medical.

·

Tonix announced data from its fully human anti-SARS-CoV-2 monoclonal antibody platform in an oral presentation at the World Antiviral Congress 2022. The presentation titled, “Platform for Generating Fully Human anti-SARS-CoV-2 Spike Therapeutic Monoclonal Antibodies” highlights the need for a broad array of monoclonal antibodies which can be scaled up quickly and potentially combined with other monoclonal antibodies to treat or prevent COVID-19. The platform is part of a broader research collaboration and option agreement with scientists at Columbia University designed to fill in important gaps in understanding the detailed immune responses to COVID-19, and to provide a foundation upon which to target vaccines and therapeutics to appropriate individuals by precision medicine.

·

In December 2022, Tonix announced that it has obtained an exclusive license from Curia Global, Inc., a leading contract research, development and manufacturing organization, for the development of three humanized murine monoclonal antibodies for the treatment or prophylaxis of SARS-CoV-2 infection, the cause of COVID-19. Immunocompromised individuals, including organ transplant recipients, are at increased risk of severe COVID-19 and poor clinical outcomes. SARS-CoV-2 has mutated to evade the existing FDA Emergency Use Authorization (EUA)-approved therapeutic monoclonal antibodies.

Recent Highlights—Financial

As of December 31, 2022, Tonix had $120.2 million of cash and cash equivalents, compared to $178.7 million as of December 31, 2021. Net proceeds from financing activities were approximately $87.8 million for full year 2022, compared to $212.5 million for the full year 2021.

Since January 1, 2023, the Company repurchased 15,700,269 shares of common stock under a $12.5 million share purchase program at prices ranging from $0.44 to $1.38 for a gross aggregate cost of approximately $12.5 million.

In January 2023, the Board of Directors approved a new $12.5 million share repurchase program. Since January 1, 2023, the Company repurchased 1,000,000 shares of common stock under this share repurchase program at $1.14 for a gross aggregate cost of $1.1 million.

Cash used in operations was approximately $98.1 million for the full year 2022, compared to $75.6 million for the full year 2021. The increase in cash outlays was primarily due to an increase in research and development (R&D) and general and administrative (G&A) activities, described below.

Cash used by investing activities for the years ended December 31, 2022, and 2021 was approximately $48.1 million and $35.3 million, respectively, related to the purchase of property and equipment.

Fourth Quarter 2022 Financial Results

R&D expenses for the fourth quarter 2022 were $24.7 million, compared to $22.3 million for the same period in 2021. The increase is predominately due to increased employee-related, facility and laboratory expenses. We expect R&D expenses to increase during 2023 as we move our clinical development programs forward and invests in our development pipeline.

G&A expenses for the fourth quarter 2022 were $8.1 million, compared to $7.3 million for the same period in 2021. The increase is primarily due to increased employee-related and financial reporting expenses.

Net loss available to common stockholders was $34.1 million, or $0.56 per share, basic and diluted, for the fourth quarter 2022, compared to net loss of $29.6 million, or $2.08 per share, basic and diluted, for the same period in 2021. The basic and diluted weighted average common shares outstanding for the fourth quarter 2022 was 61,379,692 compared to 14,230,897 shares for the same period in 2021.

Full Year 2022 Financial Results

R&D expenses for the full year 2022 were $81.9 million, compared to $68.8 million for the same period in 2021. The increase is predominately due to increased employee-related, facility and laboratory expenses. We expect R&D expenses to increase during 2023 as we move our clinical development programs forward and invest in our development pipeline.

G&A expenses for the full year 2022 were $30.2 million, compared to $23.5 million for the same period in 2021. The increase is primarily due to increased employee-related and financial reporting expenses.

Net loss available to common stockholders was $116.9 million, or $3.27 per share, basic and diluted, for the full year 2022, compared to net loss of $92.3 million, or $8.10 per share, basic and diluted, for the same period in 2021. The basic and diluted weighted average common shares outstanding for full year 2022 was 35,739,057 compared to 11,387,308 shares for the same period in 2021.

Tonix Pharmaceuticals Holding Corp.^*

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022 and interim data expected in the second quarter of 2023. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Tonix initiated a Phase 2 study in Long COVID in the third quarter of 2022. TNX-1900 (intranasal potentiated oxytocin), a small molecule in development for chronic migraine, is being studied in a potential pivotal Phase 2 study that initiated enrollment in the first quarter of 2023 and for which interim data is expected in the fourth quarter of 2023. TNX-601 ER (tianeptine hemioxalate extended-release tablets) is a once-daily formulation of tianeptine being developed as a potential treatment for major depressive disorder (MDD) with a Phase 2 study expected to be initiated in the first quarter of 2023. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted Breakthrough Therapy designation by the FDA. A Phase 2 study of TNX-1300 is expected to be initiated in the second quarter of 2023. Tonix’s rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan Drug designation by the FDA. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the second quarter of 2023. Tonix’s infectious disease pipeline includes a vaccine in development to prevent smallpox and mpox, TNX-801; a next-generation vaccine to prevent COVID-19, TNX-1850; a platform to make fully human and murine monoclonal antibodies to treat COVID-19, TNX-3600 and TNX-4100, respectively; and humanized anti-SARS-CoV-2 monoclonal antibodies, TNX-3800; and a class of broad-spectrum small molecule oral antivirals, TNX-3900. TNX-801, Tonix’s vaccine in development to prevent smallpox and mpox, also serves as the live virus vaccine platform or recombinant pox vaccine (RPV) platform for other infectious diseases. A Phase 1 study of TNX-801 is expected to be initiated in the second half of 2023.

*All of Tonix’s product candidates are investigational new drugs or biologics and have not been approved for any indication.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic and social and economic unrest; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report as filed with the Securities and Exchange Commission (the “SEC”) and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

TONIX PHARMACEUTICALS HOLDING CORP.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In Thousands, Except Share and Per Share Amounts)

(unaudited)


	Year Ended December 31,						Three Months Ended December 31,
	2022			2021			2022			2021
COSTS AND EXPENSES:
Research and development	$	81,876		$	68,838		$	24,674		$	22,296
General and administrative		30,215			23,474			8,054			7,183
		112,091			92,312			32,728			29,479

Operating loss		(112,091	)		(92,312	)		(32,728	)		(29,479	)

Interest income, net		1,873			25			1,048			(74	)

Net loss		(110,218	)		(92,287	)		(31,680	)		(29,553	)

Preferred stock deemed dividend		6,659			—			2,404			—

Net loss available to common stockholders	$	(116,877	)	$	(92,287	)	$	(34,084	)	$	(29,553	)

Net loss per common share, basic and diluted	$	(3.27	)	$	(8.10	)	$	(0.56	)	$	(2.08	)

Weighted average common shares outstanding, basic and diluted		35,739,057			11,387,308			61,379,692			14,230,897

TONIX PHARMACEUTICALS HOLDING CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In Thousands)

(Unaudited)

	December 31, 2022¹		December 31, 2021¹
Assets
Cash and cash equivalents	$	120,229	$	178,660
Prepaid expenses and other		10,548		10,389
Total current assets		130,777		189,049
Other non-current assets		94,913		51 ,851
Total assets	$	225,690	$	240,900

Liabilities and stockholders’ equity
Total liabilities	$	18,508	$	22,183
Stockholders’ equity		207,182		218,717
Total liabilities and stockholders’ equity	$	225,690	$	240,900

¹The condensed consolidated balance sheet for the years ended December 31, 2022 and December 31, 2021 has been derived from the audited financial statements but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

Contacts

Jessica Morris (corporate)

Tonix Pharmaceuticals

investor.relations@tonixpharma.com

(862) 904-8182

Olipriya Das, Ph.D. (media)

Russo Partners

Olipriya.Das@russopartnersllc.com

(646) 942-5588

Peter Vozzo (investors)

ICR Westwicke

peter.vozzo@westwicke.com

(443) 213-0505

EX-101.SCH 3 tnxp-20230313.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 tnxp-20230313_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 tnxp-20230313_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Mar. 13, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Mar. 13, 2023
Entity File Number	001-36019
Entity Registrant Name	TONIX PHARMACEUTICALS HOLDING CORP.
Entity Central Index Key	0001430306
Entity Tax Identification Number	26-1434750
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	26 Main Street
Entity Address, City or Town	Chatham
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07928
City Area Code	(862)
Local Phone Number	904-8182
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock
Trading Symbol	TNXP
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 7 tnxp-8k_031323_htm.xml IDEA: XBRL DOCUMENT 0001430306 2023-03-13 2023-03-13 iso4217:USD shares iso4217:USD shares 0001430306 false 8-K 8-K 8-K 2023-03-13 2023-03-13 TONIX PHARMACEUTICALS HOLDING CORP. NV 001-36019 26-1434750 26 Main Street Chatham NJ 07928 (862) 904-8182 false false false false Common Stock TNXP NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( +8X;58'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "V.&U6@*_18^X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)O)VG40^CVHGA2$%Q0O(5D=C?8-"$9:??M3>MN%]$'\)B9/]]\ M ].:J$Q(^)Q"Q$0.\]7D^R$K$S?L0!050#8']#K7)3&4YBXDKZD\TQZB-A]Z MC]!P?@L>25M-&F9@%5S1XT 91"V =?/$ M>)SZ%BZ &4:8?/XNH%V)2_5/[-(!=DI.V:VI<1SK42ZYLH. MZ?'EV7=R@V9 M]&"P_,I.T3'BAITGO\J[^^T#ZQK>R(K+2LBM$(K?J&OQ/KO^\+L(^V#=SOUC MX[-@U\*ON^B^ %!+ P04 " "V.&U6F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M +8X;59+ Q&PO=V]R:W-H965T&UL MG9AM<^(V$,>_BL:=Z=S-A/@!0D@*S!"27.@EQ W7"&?:+3SSQ56+L"7?8S^F*S9CYDH<*1FZI$O.,"#X9R?JE,^T@?O' M[^JWQV^DX M)%IK([-=,!!D7&Q_Z>LN$7L![>Z!@& 7$!3%G96947"50YP9CN4+4WW7@)0]X4:[L*MM6' @[(&J4^*W3TC@!>W_ MAKM 4&($)490Z+4Q#/+7:*&-@HGZNXYHJ]"I5[#5>ZES&K&! ^6IF7IASO#7 M7_RN]QO"UR[YVICZ\%I&:ZA%0^9O.:N#P\-[K<\(1*>$Z* J(R"("XK;E*[J M*/#X)4TU0SC.2HZSXY(1,L5E3&Y$3*#X:O."*Y5EU%1'W1*MBPK>",/-&[GE M*2/3=;:HKVUO,'Z>3[R2\ M&ST]C,8W7^:3\>A^1NX>[Z\GTT]D_/@4GB*TO9*V=PSM&.96T91,1,Q>R6?V M5L>+*WF0Q$[;:WM=!.NBQ+HX!FM.7\DD!C:^Y!$M//WP%..*0;<%>)WS,P_! M\[W*0[UC "95Q[=0WJ$^_8I![1N\? SF* M8[!'??)^0.[A/O(HZLEPR:!+'J#QPYLJZ#\89=4'?-3&?Z(3"Z[1Z?B_ B*KVX..^_DUQ8YB U&396NQL3==2X4)-O=VO>H"/6_=, MICSBAHL5?-P&.CQ-:WEPE4:>ROQ]W*M#Q5H1I(?!%[9=@L$J"!:+C\OE@?G# M]9K(@LKV ]R8?R*;:+T&LB; !ME&P,KR ]R?Y]S .D@NB1]\6'PD,Q:MH=YJ MVWF#DJU/:8U>1L\8VMYZ'S?FN:*Q+;'96[:0M076)##]'F(DE:T'N 6_9X7< MO$8)%2MV<(G6(#0=S:Y'?V!,E9\'1_GY3<;4RF;I$RB8Q+I$3D7]_/W/I;^[ MMW6TVW!8D<,3-4G9$H2\TW/P9K7=V6X'1N;%;G(A#>Q-B\.$4:AW>P-<7TII MW@=V@UK^?V'X+U!+ P04 " "V.&U6GZ ;\+$" #B# #0 'AL+W-T M>6QEO%DN7/Z MZZ>S;"=I=67=A['-HN M6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2 MK"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP( M&K XU7=>&18/QA<0&>7= MJ?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N- M9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W] MK;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LU MF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ> MDO:C_S=7^2V,D_'T7!S1JP,Z6PEY7>>9 ]IV03NA1.XJRY/K%.?7A M'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD\%G'!QR>(W?#$T%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/ M9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@> MF*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%' M, ; 4/2='@//GL?)=-[*CG_5U/\!%!+ P04 " "V.&U6EXJ[', 3 M @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/ MV!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%" MKM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0 MT^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( +8X;5:J MQ"(6,P$ "(" / >&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5*A^P%K0A M#5%>0-N0I@V-B??0NM0BB2O'A8VOG]NJ&M)>]I31=B M;FJ19IZFL:C!VWA'#02=5,3>BD(^IK%AL&6L <2[=)IEL]1;#&:Y&+6VG-X" M$B@$*2C9$7N$2_R==S Y8\0#.I3OW/1W!R;Q&-#C%B/%*0:S; M%4S.Y68R#/; @L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\@RX/J!5Z M0B? :ROPS-0V&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!=09#K+&) M)@G60VY6= ;N\N@#FW+()FKJIBF>HPYX4P[V1D\E5!B@?%.9J+SV4VPYZ8Y> M9WK_,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04 " "V.&U6)!Z;HJT #X M 0 &@ 'AL+U]R96QS+W=O[IFBG#S^0W1U MW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@ M;6E6?;!/3K3G>1,)KM\,<'AT_@%02P,$% @ MCAM5F60>9(9 M 0 SP, !, !;0V]N=&5N=%]4>7!E&ULK9--3L,P$(6O$F5;)2XL M6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4 M'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY M'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?K MT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y; M@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$" M% ,4 " "V.&U6!T%-8H$ "Q $ @ $ 9&]C M4')O<',O87!P+GAM;%!+ 0(4 Q0 ( +8X;5: K]%C[@ "L" 1 M " :\ !D;V-0&UL4$L! A0#% @ MCAM5DL#%S="! :Q !@ M ("!#0@ 'AL+W=O7!E&UL4$L%!@ ) D /@( ' -D3 $! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://tonixpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tnxp-8k_031323.htm ex99-01.htm tnxp-20230313.xsd tnxp-20230313_lab.xml tnxp-20230313_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tnxp-8k_031323.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 25 }, "contextCount": 1, "dts": { "inline": { "local": [ "tnxp-8k_031323.htm" ] }, "labelLink": { "local": [ "tnxp-20230313_lab.xml" ] }, "presentationLink": { "local": [ "tnxp-20230313_pre.xml" ] }, "schema": { "local": [ "tnxp-20230313.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "TNXP", "nsuri": "http://tonixpharma.com/20230313", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "span", "span", "b", "p", "body", "html" ], "baseRef": "tnxp-8k_031323.htm", "contextRef": "From2023-03-13to2023-03-13", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://tonixpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "b", "p", "body", "html" ], "baseRef": "tnxp-8k_031323.htm", "contextRef": "From2023-03-13to2023-03-13", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001387131-23-003349-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001387131-23-003349-xbrl.zip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
*59,%%6J%; ID2 MTR1'BWNZ9_*AF=^3QV.VS]U0I!B]>_Q=-1UBL64&5B3S3]0&DQDHV6(.1>B% M(RXX-?WYJO;RG86]96=M++0[S6[U7B;.7W7AZ"\D GE9TJ[?X_T!/=VK;&73 M\'(IVTUY%6[RF\AHFB)=D54)(.I5WYR5O8*MM#>P8^*Y(/)MG"J6OY.&??*2 MRF,DDDQ-0D%Y6)1.?!,L7 M 194FRS6FBNAD%\=+RG3K\W=Y'QFX4")BX1Z[B\VI*P,K=RNU0[,F+(ONGAI M%@)FK!H46@O'=N]Y)+7SBE_4>9!]$(*E*.A&542WIQ<;1:485^,#D]8Q5!2N MG\GW?B*J5E6 R_24DG*YM$#+V(UG?<&9:]GVE%[#X[446?6&==NVL(*N+304 M:E7;%KH]Z\EHG:XM+QF!UU,5R0SQAJ*;N%)C-*<4%>)L.B5UAS*.%*:QGH0J M7*D@$Q/?M[>WU0B_4LY@%:C]I6!&.?FK7?%C%3,%(U]^HIE_6(J&4B)\S&C M:A"Z>%D6[W4F[U7\O'QP:/#H"&_%U="B,:G9'ZD=+4W"FR1 MPO4WZ%EXH_2;&3I<)(%#L]_%/63VCU)%W2&2WH(,,J,QU:M5R852(5@42H%C M-4#:EK&+@4V,6#"$/J#2<'I[(%0Y)?-B2OTC1KFJD2&_2OV6:CG-LJ2T2%TO M+6EZ.R>I\))O2[M3UC,>PSC "BH*2&PJ1[+"KY#!>+"L;@ M1,6!R/11 8,7) D0;X!6*$EA)6DQUJ6;9ZD.QOB]\HNPUC,0$^V'A=BZD:I( M\'$L]25>(6(FM"2]R"=J[F7BB/OP _ "59B$1L2[NL(!=*3$+[!+,1BIT !"DM35'2SL"BLR>&2:0F<, M8C?AW8*?3##XYIDJ815#P"L"X%;P.9DGSFP8!R&=]X$Y2VP%OZ+L1HP!8CU@ M!CQ9]*#QB*@H/UW>P3T2@N,A!N3)&<83!6]!!4$Z>B0-*M6%.**JNCAT0L[297G+4 HFV0QE$3R8+L ./R!KTWNE: [H0S)!,C:2 M@$ D;X(&!R93:9(AAN%[;KJ&FO M6_B<:6_8ZVK!IZJG5'(#2%\EM4*VN'ROBX(.2349:X\[U^1?;8/1(4 M1"3R#P@H\+'<1(^@94^"*8>4M!\!\#=Q"YSM@JA"Z9;:+2D:$4A4I+[@G[#! MK#O7I:YF(\SLXYL8%LLIA;O3.WN;],[3I'>6EV."5(>WTEM3:5\/2#>>O63W@ M;IF/UH8W27BRGF4$6#4%KGN)6+OXYZN]192MD"9+%[3T!V;<^5"ZHV+Z^/%W MA5>)OI0\'H:Q^R#]*E1]&2KN5T-46=;#= P*L5S-\P^SQVNZY7<.BTW#._?Z MHFFE^>1XQ,3GC[29^H^TF1_Q9-;FQZ(^-1]5GYI"G9\#.PNC*\: @>[E ,R\ MSL41Z_VWC[;@X*W!;C%V"F2 6JE8 F2?"Q!=ZSQ8M. &FIMAJMUG8!36NS><=8S??0]]6*(-.*'@7-Y5572(G\[^KK0?/+BM?6[]V- M/I%VW6KO[:Y:93T@BD_UA2!@MVVUF^V?& &-'6MW;^=G1D##:NP_(@M\'\V[ MPB#Y=>4=TWMMGO4-G"]U2==\Q_#Q'6*\WK-K^4@1APP8/P.%^ MPVK6E^(6&Q0^Q")H6'N-)NOV,=U6L M6G]3&^VS@>9Y0?/=M<\*T_44\Y*J,0LVP\4+WDNID!_<",8,RI-$)'X:##8V M<=FO(\#:SL:/_1H,;CU>6'MC06R@>9;0?'<+(FT$]HP]AWH=\X0_FC\$GFNC MO?>#;:I9MW;;M1]L4^"YMEI+UN1&[SQOV;J!YAGKG17&:C\08Q%@(T75-7^$ MXZ3P;C..;\))SC^5!;QK[;:>))'STV!0#UM1+RA^S0:?#PD*6#NU3:G,"Z#( MC9Y0?,,38Y&M>5'#VB%_6!1I5_P8&%%OV,C&0,L7U9O_;7+IJ[WKM7> M6_)2"S?ZD%#<3X7$8D]_@\.'X+"Y8]7:]YH>&QP^/([QU3C5:&?M#!CIK16U;!AF/IH_C#M]2$[-7AQ[6'8+TH\^0!T=N'2[=T MZM?CB;@OC(3_& A-YZ5M$/HH"$V'@6X0^C@4FHQ1?1J$)HKD#;6=_/IVEJ9O MK-8U?SL^WM_?W?VBEK'M3C) MVX#[1?@O[!YXKT \OKRXS@$^YC/'G;^]CQ26BB6!TK+M0&G&'XW[K&?'?>+K M#A<1]C4;_#DQ6[\3LT_7>BJ+@E>'G3 446&.^N'\\^5L^##C\0N6O--A_YY@ M;A#X+8,C6@VU=O]>!$F7AZH9I(U_ 6/6N>&N&KBT(.S4,NV_WWUZF<9S:\11 MS=.-OQ>[$XV:U6@L%7;>^8[BT_HNT.^UK=W=I1S#VM _B3A7R$+[.]9^ M?;WK\C^B!'D\YZ!59U:[55_A6;T F;0RA*M$U7JD_CA1W\=)6!==8FBTK-W] M=:LDOI3@GSL2=FK6?NUQD/!D'N[7!WXTLIA.1&1O,?_#1^V(U]$YO1Z$DW):[U6Q#^B1=\ MUMBKWYNN?VH#_,M=S9S5[7ZQFP]^(.=5X>.[2]/5P*M0@99J6/!<\",LEG/L]8DNY2J+SI3P;F_*0 M#87P&.#5N<&IYVH@O6 ZJ<[TV'/@FLR,:)PR/Y(TA5M/GJ?9T'IN+2]\)'$/2L[0\> 31 M,&B"-\P)O6J<>C\WXCU\I+4=/4^]&@B7""'\5X2O4P/EJW!PC_2BK?9N8YOMUW8J M;=+/3S&[^*N/\])U@,+GG!UQ>*0_K1Y5V=9,C!S^F.=Y%8>A9'T>1![=K7Z4 M10WH50#]7P&^P=HY]D#4!^TW^]9=D6X;$ M'['(Z=7A:?>*?81E;QW[DWBD-7V$NGJ#4/_KUJS]F$>WL]/<9HUZLU)KU5J/ M*'67#O".LLK] W;IDZ!YR\YX&#V;*LLGK'E\]135;HERR^,>WO'F_>71[X?X MEY/K\S/XR_\'4$L#!!0 ( +&2_4P, ,(, 1 =&YX<"TR M,#(S,#,Q,RYX\[976E72NLH"1EZ!JFHX&W'JU0=!-P7 >7# MMG/?Q'L^PG@#W0?@@9#WMQ<3W9'6D6JZ[G@\ MKG#Q3,9"/JJ*+\+-!+N:Z%A-U*I)-?]M1N]0Y4_(7W95--Y+;FEO%//]^*3/ MO4Z7_/Q^WK]IC'>"/]? ONJPL?^M'_[HO8Q#U>GP7UT_ =T[[]P=GV4A6\H? M04B0.0RNVHZM+R]O7*$.71KU:KG]CJ7W13G9,!FPBA_7 7W&HV&FWH+Z!(R MZ4M62-==Z^X3!1-EXZ6OX"E7FG!_#A_H"6$6O.-FSCDH70G=S:"T@ :P@%/@ M5X;BV34.@Z_5"F"L$"0: (>$-5/19746,51"GZJ%W!C70F=T[14_1*!6JV: MNN8(=U>]FPE6"TZ3:$1D2&QC6F"]6O=,"L @!*[/A Q/84!B9G)YB@FC PJ! M@S210]"VTU1$?'A;L.A8PKDPC6VF*[=86Q11T[G&\*%EC[@I!8,[DSFR"S-2 M:^6MWST1YF9P$ W:3K:T0D8VE0I@0#E-X^7CXR%LAR6VY9EE2FFYB^ 9B5A! M<,T/TW4D01E>6L"E,>3$'+*&Y!/FQZP<9YK*2DIN*#9JNG7%B-S" *6CU;0M MT'84M9>;D]M&$@9M1_,DPL4)_3:E54R+%! K_EX57ZV#VX5MH=JF02<75<* MZK-".#.5SF7QU=LLC^(!-#GD MO&-R7,/H_O.(]4IM2!S+5VH*5K):QH%5<] M7//6I_,6,_U66PV$+V*NY4N9H9BE%!_;=>;TCTVY/L@.P;;"MF&WZ(+EX*M: MH.5F:F;Y%U!+ P04 " "W.&U6&:M):/X* " A@ %0 '1N>' M,C R M,S S,3-?;&%B+GAM;,V=76_CN!6&[POT/[#N30N,XXF#;9'L9!<93[(P-IND ML6>V[:)8T!+C")')@)(3^]^7%$59HG@D)45)SL6,1WP/]5)\3%)?QY]^W&U2 M]$)XEC!Z/CH^^CA"A$8L3NCZ?/1U,;Y8S.;S$D39"WYE M_"D[BMAF6(6+'.?;K*KMX^YC^4>%?TH3^G0F_UKAC"!QO&AVMLN2\Y'<;[G; MUY,CQM>3Z<>/QY-__G*]B![)!H\3*H];1$8Z2M9BBSL^/3V=%*5:VE+N5CS5 M^SB9:#M5S:(TZ=#7G&3)65;8NV81SHMN[]T- A7R?V,M&\M-X^/I^.3X:)?% M(WWPBR/(64KNR0,JFGF6[Y\%2EDB21B5VQXY>;";23F?R/@))6N/X_ M-* >[[P)2Y;C]%WFZY'.;=^0]QWQ0YS[(RW&>?*^(UV+_+_8SMN6WWQX[<&1;++Q01&8FU25M$Q A=[*":&LNZJ=A8UZDWE:,YXN^UR9BSJS$AT MM&8ODY@DHN[I5'X8RP]%L\5_?I\QL1*X6&4YQU&N:RJ:<3ZRE$],2U)YP;4O MS*.>QI6*2<3$U/2_IJHI7AT7L C#:D'&2L2V/ MR)MZI>X6.DJEHTTJ%'))1>CXZV+T0Z%!OVG5?SY-#K4XZ&BQ!-IN",V7HD9+ M"YK%KKK99DKW>+H@M(M M3N_),^-=^#1EKJFQF31AJ6N"8L1B#$1#:9$2>R+B'UMQQDYXNN^%HJ5TS05@ MU43#D 5%A]T;"$@E]\O(DF.:)7( ZX6D+75^N@&8;9UZ&+J@. ',P:R:%MBPR4M;&10QH#V0F2("E2'A8'/Y(E?G8IDTL+$U MO4]X6K:[^*G$P2)D.AQ(41&&9)PGDFJW(7H8:BE=TP-8-;DQ9$$18_<&LJ+D MJ-#[A^22QH,0J71^ #%LVO$H10'"T736AX90^P3C*LDBG"HO5V);UM$\B]8U M(*!=$Y*6,"A0('<@+"I ,U.$> 7F7P3S8;C4E'Y@:5FUHU+) @3%]-:'B=1[ M@62VY;SA&IYQ8*FSF[(]9JO[LX N"%!ZS+7NVBIY Q1/,] ES9-\+Y^GN]EN M5H1;&M>6N&(#,J>9,,N#8 $P93*@9$CJD!)ZZ7E]EX#F\B%&L#FFS"T!=I-- M"IJ:@$BP&@-H.&B+9TJ]$#$3(Q/'Z9S&9/VTUF '% Z'0[! @20:@9Y1.D.8T8?V:UQQUF M;"L&P/V,Q? *I2?*+52#FM!$JS,D(,"&^ 0P:X1^4,^D(";?XRDJ0+(&+\1= MQ+$X4%GYSW5"R3'8?JO6+5T==IM,680!D02[ _@IE1_T!R1CT"T-!9KI&YHZ M]0_-="@TTZ"AF;X'FN4K"P2:DS M@ %,6ZDQM.&A8S?8QT^U(-9Q7L<:M2CO_9)HF9]1IFG2/L0H37B0-(WU#BY* M[1.).Y;E./UW\MQY(FX7>\'#:M@*24,9'BHV>WW J!@D@GR<6)>XRAL:UE?) MC')WKP!;;!U> :X5!@&!S5'[%6!U]42)7'>S9)03#(P(S6)GG6PQ5?5QK2R, M+FX;:O5P\;T6&A]?9)G=);U[9!1^0* M<=73D#G=VV9Y$#T.F#)[O9"A0N?I M:KS,,)'9A^]:F;.9W;133>2Z((C>-=VTIFE=[K@W?^5)+O8\8YO-EI9W>6S/ M#0(Z5[W<:5/WN%441.]W.3-)*+6H*7:,Q8*E293D"5W_(DX^>8)MK;*)7 $! M&]0TM!5!H #:,CDX")%6.H;@CA,)(1$=4;P$*!,+\=N'!^MLWR5V!46_80T' MK P"DEY[)BPB8!S5(I *046,7VSF6;8E_$WP6$(\(02:!T!JZ4/$"3+9"Y4* M],G6@D1;,3_NCZ>K99*GMI/+ML39G 28JV8DHSP(-@!3)@M%&6(/Z'CZE]5? MD8YRW/TW;,FQ3!Z[V&]6+ 6R3UE5KB#HL*@YL$B"0 'V9=)PPU I14KK(SM5 MPZRE.4:Y*P"LMG37-PJ#Z'2;H]:7O]'7GH;\RUWT*$P1X(4$N\SUT&\S:0[_ M=4T0"'08:YV4E%*DM3Y>2#A,6>O^1<#:VR)@W;,(6(>X"%@/702LO2T"]&Y5 MBA Q+MVNTF2-@>2$G6K74'18-OFP2(-"!?8'CAE5"#K$N,YH6:0XD^GY^:;8 M_Y7X8&DEH'.6T[++9I74TB8*@I$N9ZVTEBKI7$V,I-HU%]LXR4FLS%PE%-,H MP6F5'M%V1;P_Q!DM \U7X/3HPV!HF,D63BI,YS*L @^I+EU?2EK=/S/38;CXT XB#P&F(0^#1&1DT?I)12(>55\*\ MD/2-I5N:8UZ\2\YM(Q.@UL8KR](IE3N3O120OY O.<>D- M;"\D=_U299=I\VU*FS8@A#H-@N]/5C$R50S63'E+&<-G8JFU9AU/B1LJ]XEC M6A;;N6,J24!XV'QU9)#A2&N]L+#8X#3]O,T22C)X(C)4;EFP6FRRT) $Q(+- M%\!"(45:ZX6%RPWA:S&]_<39:_Y8YF<%VP:HW;+1:;G)B%4:$"M=_@!F= A2 M,3JEKA]X=H>$XBK+(MQ2B]0Q-J!9@YF6+B1@(',M6E(2R>LM-RQ'2X:^9@3E MCP1=EC]#5\\$K^KQ]4LC421?B%"KDPWXMD-_B"N"AIK7'/7I@Z!IH$F3J2*L>7)= M!"(9Z3.;43VY/;S$:X@.,>6U[1K*\@R @ MJNH!1YA1 52B_]_QG3)[Y]SJ/]'6<1(?(IJZP: MK?JNOPV,=LO,FYK4I&E0:$":9G$&%,?@J>&>0X]L+ QI@W&3HB @(O0$VH1L.120J0C\@%8QJT9[. MS[)#%D 2?][?DP?"Y7L'2[++/XL=/76<80R(=7WV-K@YYLE<;V 0$+[5+72J MEZ%Z!6@EGQ$KJT"_R4I048OM]\OKFZ[%)[%9;Q)_K7!&Q);_ E!+ P04 M" "W.&U6MEY]B%L' #;5P %0 '1N>' M,C R,S S,3-?<')E+GAM;,V< M37/;-A"&[YWI?V#5LRQ+:IO:L9NQ%2NCB1.[EI.TO60@$I(P!@$- %K2OR] MBHH^"'!]X=H'6Z86P+[/@B"7 'CQ;I7RZ)DJS:2X;'5/3EL1%;%,F)A=MKZ, MVU?CP6C4BK0A(B%<"GK9$K+U[J^??XKLS\4O[78T9)0GY]%[&;='8BK?1I]) M2L^C#U1018Q4;Z.OA&?NB!PR3E4TD.F"4T/M%T7#Y]'O)]TW<=1N ^K]2D4B MU9>'T;;>N3$+?=[I+)?+$R&?R5*J)WT2RQ16X=@0D^EM;:>KT\U/4?R",_%T M[GY-B*:1Y27T^4JSRY9K=]/LLG\BU:S3.SWM=O[Y=#N.YS0E;28^4[FQKMM^R@/V.)YJ=Z]R]6QD3DX>]MIG( M:^'^:Y=F;7>HW>VU^]V3E4Y:)?R6VN;LQ\)RXTOI#9?Q MG@/J"W[=$Y;T_AD)I\["666>J_G/C@4O1R#_>=[WM#51!M%8E/6Q,F$ M\KS^[];FP*33@%OV'RKM*&A/GOC"A#%5]#2!\9 V'_C@G; MHQ")]Z,B0C/'!P+\V!I(_ _4&P^/1B3DXSGEW"5R1(!Z>94]$/L;3.Q^G:\ M_,VSN[[;2PN<_4X1(/X_7PO^([5($;BGBLG$7M(5@/V1,9#Z&29UCT)4WCFH+S'WS8!_*04 ^9C@DO/!K:8SJ,N$2BH[Q5+B5J/65P_:!S;0F&C9)9A@2BT'\EJE%A5;,J**<%ZZ-XB4/8H M:25(+DH(1B*6:B%W'A8+I*,$Y2I)+"Z]^7/+ M!.V&0E%I#IXCP@M 0.8KP=Y[&?8>'#M*'EHK\Y5@[[\,>Q^.'247K96)B7U@ M/]ZI1[GTS$![C:'(47+1&HF8P/,KS9VZ5_*9%2NCZJ@?E8"B1TQ1PV)1.WQQ MD8?T]M(2RALQ7:T6A\GY7FI#^']L47VCA6TIT M8 +EBY*K5LII&JF+L*+$WWWW+:! 41+0*C$-\[R5;NYC+D7P>>RQ%90K2B;I M$]7TP.O6$FOOJ;_S-7@%&\JP>BBC88S?%#/6@X%,TTQLGM%X9L4\IE"\*.E? M4%[#J,>2LY@9)F:?[!VB8H17^D3=D#R6.DNO5"\4E/](ZH^JE_"M*0:. DO9!13<]SM XL\/>NMN;/+H= M,YY1YL@*RAHEY?.):ICM9_FHB-NQ-UZG$\G]VT,J#:&$41*\@+2&(>_Y48WW MP 0*%B6SJY2#-";^'8BY+Q^40A ML2W6AMLSZF["V8SX=Y(%"X#WV6 2#TAM>O]>ON7'[>56:>['T'ZHQNXQA0+' MV2(9DM>3AK M+XM%S=MK3_'2CA!Q7PDH>,1)Q+!8I/5IACJ?V3-]3PS9>!CB[RL!Y8\XH1@6 MB[9^7@WLA6IX3SZTPS075P;#DPA$)&7/-:*0T% M\DU*U'VO9$RIFS[1V[,-D! !*X"&!#$_?1$*G,<%,DW=9B(9/XWG M5K2^RTS^#E/K7_"A0; <-#28FS@!PI'N@O2/C5XTN5X_T"E5;IG"(UV9:]O0 M4_BF"% <&A_4-PJ!,52$Z:)SI.O6'G!OJ2V^<;_'/?Z%SY*J""RAL$5/Q %G#U^HL3VB#1TM:F%=B__IVD+;30(BCH M^N[=W5FD2Q="(50T23=85JCT7=UV9)[I(_C5&,6UF0R'J12[3D:/F\==^V8*@UTY4\$)GD#&AH528#_)UW MDTYCH*L5VC7G=+6\KI3I62F]-X\.I\=XP#"J;YK3#!R2N^/FY:2[%=Y_TC5I MF5AC7=WL8PMTR"'EXBDI+NWZ@,09D0. X'OB47]]$\Y^/)/VX,PH)\@I;^Y@ M-I:X0J;$[>&$!A@A25Y'DW0CP>XFH=7K:+/X(\;&N',7LX[HZ#8$H+K/XLPV M#)7TB69%CN-]Q-B7C#>:F=;MWC7$O2]?HT.AAT&I"UON\8R:526=BPJ8)5N 3\3^'%K544CQ, M.I_0VB<61AQ,G+S8]/4H5M8U"X01;X\,4++L?#N*661H)1W33_)Q21?LX;_B M<71"B:H44(M8!ZB.^Z2 ALKP -4JXH>'E'3\<-/Z0ZJETN RIZ,1[UG>.[X@<"\!A;@7U4#(8[*(!T3JS5-(<,+,GI( M@>_+ MS4[C)P\SZX)9B+"I^/)RI^?.ABE9$E0.UR45<>T@^N2W)@PJ-E8$@/ M+1 S80_2@_# #A FGBT#I\)I:;BP,C,D10+OZ,J(?RKT%3%KI)*CF$*9H>)1 M 6FZ1L2\IL,"GX/$Y)-;?*.*0C0QU?E7Z%BW^\2DLC.+AU:3NZ 34^]SU<=3 MF7@Z8^F3GV-( R8 %:&%4.7&BA/M'B8#*%:#-:#Z6%'H/A11,L NQPL.E)BP MIA/F].!^NL#$ @P$(+&J%GK""5O:T(A[LS\Q9$K,;;; Y(]BC/;!(3IF[J(* M G?0,=TV/6S03:BRX+*,J#*79<\=><.(D/;XZ?@Y57A+EQ(3"59(Z.I6KET$ M-3,]>((N&8K/Q6: ?'5EE@H(,4RK@BU2G+#@09JTS0P#548,\EJFR0H0X#UT M11J4LZU11\A@13/2[!/,;),477,K0!\/F-<41,&A1G=."8^ M8@8/. !0XZQL^5AA$-C235_S\C*8IC$,J@]IA6AZGVIOH7U;+M-XPP![[0$I MS C4M5"?/3KNP?.-ATD8#Y_\K]]M-VV5Q!OX4:PN?E?;Q^8CU>*6;A106C+ MN;M/.KIEZ?T"RO!G ZI8/>B02OT1"PSOZ"8@=H8?JUA^1@ #,5VER@%R&SU( M3GMZTMZ%V1YG]!>L)? T5OS/O].[J0.'!?=_'PO) ^"0<,C@T/BY 'LDDFQ MNH/.B/I*+"KC'=2"(#C> G/K>LP54.H <4.+8Y4^PE<9G 0Q)Q08X?"S +]- M^[!TU)-O=:N5E"K76I76Q["3G&]2%O5\DVSUJY5 M6ZA4KZ#J7?FL5#^MHO+UU56MU:I=UQ>@1%H%);>8]2 3A?AN!U42Y0224KEL M?B[>=:MUS>#W5R&VD^OF%3ID!M:$&^4A5SZ5%I%D/%[199M'$CR,?Y#'0>\D M_/V5WS_-/KWT[U.]#H"; I-:&(PVO.R>/=9S6GUW%DQN83"]IUK^UVF[;M,> M@/EH(.7'][N#VX]?3,=X;W_G,->/C;AWIC1*W$$X)":U7H;-:N-ZV;[ M_X"AAFTR&VL6LG08)/.2"X*,4S=1.K>E;".]BZP>X4VV22U*V.9&=2CWL 8K M6DFV>'LZG\E^K20^C@ DP0->SHY)#-VTT);B?B<8@AG"+$1>H;/;3)3M A R MY4PJ4\ZD(<+EJA-,AWL57._\>KR[*!T_*;/.:6]Y>,KM[?E)_5*I53+O]@-. M\>TH1H=6@4NA#^-Z"AZ-0!1$"_,3 <*^#N\5-N4>3-\=Q,$NZZ.^<@:O>35? M-_W2"N(],?=]4.-=W*?JJ# ?KC#=J-C J9$TR2-EO*IL\1)0N-G\S-NL]?(R M,.NY%2R?87ACQ?9UO7:'&F>EYE6I7+UIU\JERQ8ZN[ZLU.JG$-0V&XG(*=H9 M*\!]L$Y/N%4=8G#MG!_'(7I\(,P0,XC,:Q8*HB!RBR%8#, ?FMN?:T 6[J@$ M&E45!"*+7:)43'PWL*)XWUTB?)G@.,&3=57%!H,TSOO)R>T/+=,;]DI,;HBJ M1PHDC*+/H:4LOQ2[-&2R0()+8MRDCST8GDMD>;[J/55)=_)PA:82S%U3/'E] MTW9JFJR;L.")O9B6!5ZV[.P'E'4E*MR^&*A*JWZZI^ZN8B7@6T:\B&41P]1? M^9P,+@4+T!DKULDK5O #K$K?K]!I?4UP\L)H.I[93:7S_^C'U8\4T$\;#VMNI5@6\WN>LKH7 M.>/BQ>[DU/V5*2N"@%A1VHVGLYGL7BZUH.K@/W-1+QO4\<+J&H]=S](H? M/ MCZXA+3+1.61%3*$B;YHN1JV/"EB4 PYO.X@ZW$I^%PF6]7Z?,O:I N/N!CFS M=OM[2*G6;*%JWU#U$3$_3TY!,T=U/;'MCSV-:2M.BC"L^$US_M6Y\(B\W7&? M)44Q"6/NQR752#K<=^NGQZ>GK-?4KU?FND-P<[>-KC!$[RW+),2*<-T[D87; M .0R_'AMMO6!%LZ36M^E[)F<[)VMHBX9@3I6+/>PU$,'"M1[:D1']:^- M9_NR7>W=D/>S'<%5 #N$@WMY:3^"G<],@EWJ> 9LF"!N:F 5D2&1;8N^\L08 MW"1AVV@+*$><]$_.@-?"]:1F\9]_[TOIO0,&/55B]'2-($TLH#N0^,NJS==# MA$V"-S=D8+[ F9^9;7EWMG%3+4'?Z/F5/4M=5/?*=_M7G17,+S^^6'%K?U?: M7M1 3ER2+W6(21N<[WGA]LG(OKO'N=V]P=,*R)[&&2OF4]GX?GI?BHROO]]L M>[(9A!@C[K.)_"QV%[ !S@^,C(?6'7V(.D35!X@Z6P\GX"S1?OP"=:D*T MUJ^/Z'BH11YU@FYJJ#7J=W1UA_&]G2TFHI1H:/K*L&:.)SF-Z]0DKAD\WO9[,'\[8'-#4W+5VE,K"C/5Z! MR?*22[AB3?VV/&K4+AO#]WO'110[2\^26IT $DZ$&95FL[B>%KR:36P$3K6 M:3:5<'I^&[5ZZ4K#)-PV^#%*L?G/7:QYW>U&+7Z2].M\4,)2[V6]=AM-UY)J M!D!QV0?I32M.9Y6XM-797DSI3M]OH_9,N-IKC-G$?%/YC3/<*^W?=:M[]#.5 M/T/=VJ= AL2S6_)B4\#MN_V= X$#U,'R\Z.I \-\ETPW"VC0HWQ_W;>,.1$4 M,2$&\T2VN>$_0R+,Q@VI0$YKC(WF$/P;;1H&RXP.O +JA!TO76HOP[^?&+EK ML8#G6+;FU>;W!@P<7@R\4.KV6?ZH%C==D= [Q?Z5P@Z MJD3J.OU16NH(FP\/!TI6RJ#VJ"'E5E$(F<89*_(80.7&DT[ '[P@"[IBD\$R&H,T*R*(\"J&=H)?RT 038P=HE M90CF$>0Q'-TC I #J\;RI.^1G\E!_2@0PG,9(Z<2D$6MCQ\ E8GB5-!OH )Q80^[N.R"Z=)7RF MPJOANG,I6DF:GPOL^'D(3P6^LH,NW,>D^W3X^G)V-NRMYBAY5(8_A[ %D_O? M(;?\5#?1G6/W.YL;--R-T)G-CQ[X"*)"R@X^0M-%T<-F1/0"@MPM%OX^#BJ2 M>N?Z+U>J0*:../8!!=S>!VLR&.SF!I;%6R1X;_XV% 6; M"G-V5Q1?_^7710\ QXO- MJU1 BG-W5$1)L]=8(V^J3MV)W16AXJ0$XB]Y3)=$9DL@?*A9] 5ILWN&4S=N M/1Z]5=];\;W;OC/LF 0_QSL$9A?P; @9^"_Z_I;T^Z_Z^F_YKFM_?F5'# 2T MD.NS[RV1O;,.MFP9(BTTN',+ M)6.3&PQDQ@ZTU51/BOKII% 6WQ9X,=4I-1!V8N;X%OZ8!MDH@$F MF8>^7%Z.L&"DZ4J0+V%\^(LM+J\(&?)K9IL;SJ)7(3+A)S!0)BU(DA*H!&N> M,3XE8(BS028LGE@LF-A""F6RS1@(#SK 0PA\ #3C47J7J@ 4\^"X1SO40OE\ M(I4&F]@1F.GX,"_T@C5[_#83OI3O.'&R<^\P\3B'>#&=/F"OB,?8Y&.G0N/FX![0FVRMQS) MD[](XRQ>P9OX.WQSA!C.'4U!2XX92#]# ;EF#L MDO1%EO0W7][RWV-YFT2;8I[RC:\KCM.[AS]C.M4=3TQ M_[;9;RC__=T_(OA9I0>I$":;U.#+YQQ?L;!%+2VD*"$L#2BLC#1OR?E@S08C MYPV99)C/QU/I1,_JQXIY9]G JYK/L6(ZE5U^TGY8":N34R.0G;OAHIMV["!% MA&/3+XM9D>C*.K E2KBHQJ<#EL5UH0JV,!+74+=X84'A109>.1=!-._*WW^- M^ NP(0MR7FZS_^ONV+7JIW62^V;9O6[ M\C(WC?._3\[9;'RQJ>D$UNS],T- 1#;5D\W(311OE6^NSAE*SK$ M[/C0MU_+D9E]64(J(@8 W#SD.XIE8HL#RTR.NZTH$%WHI5S+O\3DMQ+8M"=_ M+^WN9,JE9E^?$\['ZC3%W^]7F G9YF2V+JTA;]M:_[0ZAC&+''",3-&\ D'( M>XK63WV2)=&QB15>4V]A L[97$32RQ"[J@GYO;W/'"'_C:52[E'2]>UG7XOW M+$1(9TW%Q \FZ0ND-)D#="VJ'ZR +C&S/I3A>.E!1,HSYB8LY/>#2(6 2$WL MU?\6H(52 "&$I/>K4L3OYBDN^(M9]H\?Q $TY_;]Y!>ZD//AR=//U,7@J?2C M5TW^N!X-<^IKKOKSFCXU;VY9[?FNFI9Z=^5.YQZ$]//ISQ]6^^=K]?[VY/[> MS-[7;NYI\\92:G+=N+.;@\'EBZ%6K_3]VLM53K\DSSB5N>CV.MEJNC/9UL5VSCIV4;F+O.S:AG&5?GY^:]*LG9V?SZL M22>GIL::F7*F3^AMY:8].KYMU_[LOV34OYJ_;MC%RS"O#C,_DH/[[JENG;=_ M'!TY(OD?4$L! A0#% @ MSAM5F9&86XF,@ ]CX! L M ( ! &5X.3DM,#$N:'1M4$L! A0#% @ MSAM5F!X9+]3 P P@P M !$ ( !3S( '1N>' M,C R,S S,3,N>'-D4$L! A0#% M @ MSAM5AFK26C^"@ @(8 !4 ( !T34 '1N>' M,C R M,S S,3-?;&%B+GAM;%!+ 0(4 Q0 ( +